| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10963520 | Vaccine | 2015 | 7 Pages |
Abstract
The immunogenicity and safety observed with AS03A-H5N1 vaccine formulated with bulk antigen which had been stockpiled before vialing and administration was consistent with that previously observed with newly manufactured AS03A-H5N1 vaccine. This suggests that stockpiling bulk antigen for 4 years does not compromise the immunogenicity or reactogenicity of the vaccine.
Keywords
AS03pIMDshemagglutinin antigenmean geometric increaseMAESH5N1 vaccineCBERHemagglutination-inhibitionGMTsCHMPCISMGISAEsAesPandemic influenzaSPRStockpileWorld Health OrganizationAdverse eventsserious adverse eventsconfidence intervalsgeometric mean titersSeroconversion rateSeroprotection rateCommittee for Medicinal Products for Human UseWHOSCR
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Olivier Godeaux, Patricia Izurieta, Miguel Madariaga, Mamadou Dramé, Ping Li, David W. Vaughn,